PROJECTS

Evidence across materials, mechanisms and products

A2P2 has been applied across medical-device and adjacent regulated-product environments, including sterile barrier packaging, biopharmaceutical single-use systems, implantable polymers, biopolymers, collagen and bovine pericardium, gamma-irradiated assemblies, adhesives, tubing and industrial membrane systems.

4

INDEPENDENT STUDIES

3

POLYMER FAMILIES

2

LABORATORIES

8 yrs

FIELD SERVICE COMPARED

THE PURPOSE OF EVERY DEPLOYMENT IS THE SAME

1Identify the governing behaviour

2Design the right experiment

3Calculate a defensible time equivalence

4Connect the result to a decision the organisation can explain

WHERE A2P2 HAS BEEN APPLIED

From implantable devices to industrial membranes

Implanted pacemaker

MEDICAL DEVICES

Pacemakers

Woven vascular graft

MEDICAL DEVICES

Vascular grafts

Tissue heart valve

BIOMATERIALS

Bovine pericardium

BIOMATERIALS

Biopolymers & collagen

Bio-derived materials alongside synthetic polymers

IV bag

MEDICAL DEVICES

IV bags

Prefillable syringes

DRUG DELIVERY

COC syringes

DRUG DELIVERY

Vial adapters

Fluid-path assembly

ASSEMBLIES

Fluid-path assemblies

Opening a sterile barrier package

PACKAGING

Sterile barrier packaging

Thermoformed device trays

PACKAGING

Thermoformed trays

Single-use bioprocess bag

BIOPHARMA

Single-use bioprocess bags

Silicone tubing manifold

BIOPHARMA

Silicone tubing manifolds

Braided reinforced tubing

BIOPHARMA

Braided transfer tubing

Reinforced hose with sanitary fittings

BIOPHARMA

FEP-lined reinforced hoses

Capsule filters

BIOPHARMA

Capsule filters

Filtration membrane with micrograph

BIOPHARMA

Filtration membranes

Spiral-wound reverse osmosis membrane

INDUSTRIAL

Reverse osmosis membranes

ACROSS SECTORS

Gamma-irradiated assemblies & adhesives

Plus multilayer films, elastomers and implantable polymers

Deployments are confidential by default. The summaries below are anonymised. Study designs, source data and detailed outputs are available only where disclosure is authorised or under NDA.

VALIDATION EVIDENCE

Tested against independent evidence

Four independent studies · three polymer families · two laboratories

RETRO-1EXTERNAL LITERATURE

Medical-grade polyurethane

Hydrolysis · Arrhenius fit

A2P2 PREDICTION

Ea = 42.4 kJ/mol

PUBLISHED REFERENCE

Ea ≈ 42 kJ/mol

r² = 1.000

Within ±10% Ea criterion

RETRO-2INDUSTRY PU ELASTOMER

Poly(ether)urethane

Concurrent hydrolysis + ageing

HYDROLYSIS Ea

91.2 kJ/mol

PHYSICAL AGEING Ea

163–200 kJ/mol

9 days at 50°C ≡ 4 years at 37°C

Concurrent mechanisms integrated

RETRO-3STERILE BARRIER PACKAGING

PET tray + sealing film

System-level physical ageing

TRAY

Ea > 300 kJ/mol · Q10 ≈ 10

FILM

Ea ≈ 118 kJ/mol · Q10 ≈ 4

Assembly Q10 ≈ 7

9–12 months validation time saved

PROSP-1FIELD REAL-TIME

PA/PSU/PET composite membrane

8-year continuous service

A2P2 PREDICTION

0.9%/year rejection loss

FIELD OBSERVATION

0.875–0.9%/year confirmed

95% prediction limit overlap met

Cross-material anchor established

Cross-material reproducibility confirmed across three chemically distinct polymer families: poly(ether)urethane, PET assembly and PA/PSU/PET composite, across two independent laboratories and five independent datasets.

±10% Ear² ≥ 0.9595% prediction limit overlap

Currently under FDA MDDT review

Referenced in active ASTM F1980 revision

SELECTED OUTCOMES

What the evidence changed

337 → 71 days

AGEING PATHWAY

Bioreactor stability programme

A material-specific A2P2 programme reduced an ageing pathway from 337 days to 71 days while retaining an explicit scientific basis for the acceleration conditions and verification plan.

≈ £40M

AVOIDED WASTE

Adhesive shelf-life extension

A2P2 supported an evidence-led shelf-life extension associated with approximately £40 million in avoided waste. The work focused on the governing adhesive behaviour rather than treating the full assembly as a uniform ageing system.

8 years

CONTINUOUS FIELD SERVICE

Membrane field validation

A2P2 predictions for a polyamide composite separation membrane were evaluated against eight years of continuous service in pharmaceutical-grade water operation, providing a long-duration comparison between accelerated prediction and field behaviour.

Extended

OPERATIONAL LIFE

Tubing life-cycle programme

A combined cleaning, drying, inspection and performance-verification programme extended operational tubing life beyond the original replacement interval while maintaining defined acceptance criteria.

DISCUSS THE RELEVANT EVIDENCE

Request an anonymised technical discussion

Qualified organisations can request an anonymised technical discussion under NDA.

NAZLI@GULSINELTD.COM

TESTED AGAINST INDEPENDENT EVIDENCE

Prediction against independent evidence.

PredictionIndependent evidence